AGC Biologics has partnered with Quell Therapeutics to support the development of multiple Treg cell therapy drug candidates.

GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.

Chandigarh: In a significant move to strengthen healthcare delivery at the grassroots level, the Punjab health department has ...

India already has a homegrown CAR T-cell therapy, and other regions are exploring their own strategies, including developing them at the point of care.

From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder ...

Carbona remade BioLife into AveXis: Av for adeno-associated virus serotype 9, the engine of Kaspar’s drug; ve for vector; X for the DNA helix; and Is for Isis, the goddess of children ...

The Cambridge factory, for its part, boasts a “broad-range” of viral vector manufacturing process technologies, with multiple drug substance suites, an automated fill-finish system ...

Viral vector-borne diseases can’t be treated. Parasitic infections, like those that cause malaria, can be treated using drugs like quinone, which kills the parasite or prevents its growth.

Pharmacy benefit managers are driving up drug costs for millions of people, employers and the government. Credit...Photo illustration by Jens Mortensen for The New York Times Supported by By ...

There have been more than 20 approvals for viral vector-based cell and gene therapies in the last ... especially when weighing the cost against the inherently risky nature of drug development.

Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China ‡ Beijing Key Laboratory of Drug Target Research ... In ...